The Surging News reporter Li Xiaoxiao comprehensively reported
According to the Wall Street Journal reported on February 5, the new crown vaccine jointly developed by the University of Oxford and AstraZeneca in the United Kingdom is 75% effective against the mutant strain found in the United Kingdom.
In a study published online Friday, researchers examined blood samples from 256 people involved in the clinical trial, and less than a third of the participants were infected with new variants of the virus, the Wall Street Journal said. The researchers eventually found that in 75 percent of cases with symptoms of infection, the vaccine triggered an effective immune response against a new variant of the virus, and if no symptoms were included, about two-thirds of the cases triggered an effective immune response.
The Wall Street Journal stressed that the findings are from small-scale studies and are preliminary results that have not yet been formally reviewed by other scientists.
In addition, according to Reuters news on February 5, Andrew Pollard, principal researcher of the Oxford Vaccine Trial, said that data from the chadox1 vaccine trial conducted in the United Kingdom showed that the AstraZeneca/Oxford covid-19 vaccine can not only resist the initial virus, but also the new variant b.1.1.7.
Sarah Gilbert, co-developer of the vaccine, said that while the vaccine is effective against the virus variants found in the UK, it may need to be adapted to future variants and we are working with AstraZeneca to optimize it if necessary.
The news came from the University of Oxford, which reported that the results of the study were published in an uncollected preprint and a detailed analysis of recent findings showed that after vaccination, the shedding time of the virus and the viral load were reduced, which could lead to a reduction in the spread of the disease.
On November 23, 2020, AstraZeneca announced that its COVID-19 vaccine, azd122, in collaboration with the University of Oxford, is effective against COVID-19 with an average effectiveness of 70%. On 30 December 2020, the vaccine was authorised for emergency use in the UK. On January 29, the European Food and Drug Administration approved the emergency use of the AstraZeneca vaccine in 27 EU countries.
The problem of virus mutation has become an important problem facing the current global covid-19 vaccine research and development. According to the surging news, in response to the mutant virus, on February 4, local time, the United Kingdom launched a trial to "mix" the two new crown vaccines produced by Pfizer in the United States and AstraZeneca in the United Kingdom in a two-dose course, so as to assess whether it can cause a "strengthened version" of the immune response and whether it can fight the mutant virus.
Other vaccines around the world have released data or conducted further research on COVID-19 variants.
On January 28, the US biotechnology company Novavax said that its new crown vaccine is more than 85% effective against the new crown variant virus found in the United Kingdom; on January 29, Johnson & Johnson said in the announcement of the results of the phase III clinical study that its research on the new crown vaccine ad26.cov2.s also has the ability to fight against the new crown mutation virus strain originally found in South Africa.
On January 25, the United States Modena Company announced that for the first discovery of the B.1.351 variant in the Republic of South Africa, the preclinical and Phase 1 clinical studies were launched to test a mna vaccine (MRNA-1273.351) against the mutant strain of the new crown virus as an enhanced vaccine efficacy.
In terms of the new crown vaccine in Biontech, Germany, the results of an early in vitro study showed that the vaccine has the same protective effect on the mutant virus found in the UK, but further research is still under way for the South African variant virus.
Editor-in-Charge: It's Winter
Proofreader: Luan Meng